Sonelokimab Drug Market Insights and Forecast to 2032
A new report analyzes the market potential for the drug sonelokimab for the rare skin condition hidradenitis suppurativa (HS). The report covers markets in the US, Europe, and Japan.
ResearchAndMarkets.com has released a new report detailing market insights and forecasts for the drug sonelokimab through 2032. The report focuses on sonelokimab's application in treating hidradenitis suppurativa (HS), a chronic inflammatory skin condition causing painful nodules and abscesses.
Sonelokimab, also known as M1095, is an investigational drug that targets IL-17A and IL-17F cytokines, which are key drivers of inflammation in HS. The drug has advanced to Phase II clinical trials and is expected to improve patient outcomes due to its ability to inhibit pro-inflammatory cytokine dimers.
The report provides market analysis across the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan. It includes detailed information on sonelokimab's mechanism of action, dosage, and research and development activities, including regulatory milestones. Future market assessments are also provided, projecting sales up to 2032.
In February 2023, enrollment for a global Phase II clinical trial evaluating sonelokimab's efficacy and safety in moderate-to-severe HS was completed ahead of schedule. The drug is anticipated to offer new therapeutic options for HS patients who have limited treatment alternatives.